Clearside Biomedical, Inc. Completes $20 Million Series C Financing
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
